New pill takes on tough breast cancer in first human trial

NCT ID NCT07581314

Not yet recruiting Disease control Sponsor: Telomir Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests an oral drug called Zn-Telomir in 76 adults with advanced or metastatic triple-negative breast cancer that has worsened after prior treatments. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. It is the first time this drug is being tested in humans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Zn-Telomir (oral capsules that regulate metals and protect telomeres)
What this could lead to: If it works, this could point toward a new oral treatment option for advanced triple-negative breast cancer, a hard-to-treat cancer.
What could go wrong: This is a very early first-in-human trial with only 76 participants, so safety and effectiveness are not yet known. Many early cancer drugs fail to show benefit in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED TRIPLE-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED TRIPLE-NEGATIVE BREAST CANCER METASTATIC TRIPLE-NEGATIVE BREAST CANCER TRIPLE-NEGATIVE BREAST CANCER (TNBC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.